Well, well, well…..looks like Social Capital Hedosophia, will beat Chardan Healthcare 2 to the punch by being the first IPO out the door post-Covid lockdown. Social Capital Hedosophia intends to price the larger of their two deals tonight (IPOC.U), for trading Wednesday, at $600 million in gross proceeds.
If you recall, Social Capital Hedosophia III (IPOC.U) intends to focus on technology companies OUTSIDE the United States, whereas Social Capital Hedosophia II (IPOB.U), the smaller of the two at $300 million, intends to focus on technology companies IN the United States. Perhaps Chamath and the team feel there are better opportunities abroad? Or maybe since it’s the bigger deal, he’s hoping to find an attractive unicorn now that the traditional IPO window is effectively shut. Or it could be they just want to get the harder deal done first (it’s not easy raising $600 million). Probably all of the above.
Regardless, both IPOB.U and IPOC.U, recently re-filed and changed their warrants from 1/4 to 1/3. Plus, both deals are not removing any interest from trust to fund their working capital AND both have the Crescent Term with a threshold of $9.20. These terms should work and pricing seems a lock. The Social Capital team already has a successful deal under their belt and they are a brand name, elite team. And frankly, investors have been sitting on the sidelines for over a month now, so many are eager to put money to work. Look for IPOC.U to price shortly thereafter.
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...
At the SPAC of Dawn Ever since Digital World announced its combination with Trump Media (NASDAQ:DJT) back in October 2021, it was clear that SPACworld and the Trump show were set to be intertwined for quite some time. And, although not every headline has a bearing on the wider SPAC world, Trump Media’s post-close rise...
AltC (NYSE:ALCC) has reportedly been taking the pitch deck for its combination with nuclear fission firm Oklo on the road in recent weeks, which has generated the rare result of a SPAC trading significantly above its trust value still well before completing its deal. The SPAC has an estimated $10.59 per share in its trust...